Dopaminergic Agents in Rheumatoid Arthritis

J Neuroimmune Pharmacol. 2020 Mar;15(1):48-56. doi: 10.1007/s11481-019-09850-5. Epub 2019 Apr 23.

Abstract

Clinical evidences suggest a causal relationship between rheumatoid arthritis (RA) and the dopaminergic system, and several studies described an alteration of the disease in patients treated with dopaminergic agents. Despite these interesting results, potential direct effects of dopamine on RA have not been intensively considered until the last decade. Recent studies confirm a direct effect of dopamine on the systemic immune response as well as on bone remodeling and on joint inflammation, both in humans and in different animal models of arthritis. While more research is necessary to accurately determine the effect of dopamine in RA, these results are encouraging and support a possible use of dopaminergic drugs for the treatment of arthritis in the future. Moreover, they point out that dopaminergic agents use to treat comorbidities, might influence the immune response and the disease progression in RA patients. This review summarizes the current knowledge about the effects of dopaminergic drugs on RA and describes the potential of dopaminergic drugs as future therapeutic strategy in arthritis. Graphical Abstract.

Keywords: Dopamine; Dopaminergic receptors; Rheumatoid arthritis.

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology*
  • Arthritis, Rheumatoid / metabolism
  • Disease Progression
  • Dopamine / immunology*
  • Dopamine / metabolism
  • Dopamine Agents / pharmacology
  • Dopamine Agents / therapeutic use*
  • Humans
  • Immunity, Cellular / drug effects
  • Immunity, Cellular / physiology

Substances

  • Dopamine Agents
  • Dopamine